Business
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
Organizational restructuring and operating cost reduction initiatives on track SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences Holdings, Inc. (Maravai)
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":"\nOrganizational restructuring and operating cost reduction initiatives on track\n\n SAN DIEGO--(BUSINESS WIRE)--\nMaravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates.\n\nQuarterly Results:\n\n\nRevenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million\n\n\n“We exited the third quarter confident about the future of our business. Cygnus continues to perform well and TriLink, although lumpy by nature, shows strong funnel and order velocity. We expect TriLink to deliver double digit sequential revenue growth in the fourth quarter,\" said Bernd Brust, CEO, Maravai LifeSciences.\n\nBrust continued, “The work we’ve done to reset, refocus, and strengthen the company positions us to deliver attractive financial results in the fourth quarter and 2026 while continuing to serve our customers with the same level of dedication we’ve had in the past.\"\n\nRevenue Guidance for Full Year 2025\n\nRevenue for the full year 2025 is expected to be approximately $185.0 million.\n\nMaravai’s revenue guidance for the full year 2025 is based on current expectations and does not include revenue, if any, from high-volume CleanCap orders for commercial phase vaccine programs, or potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.\n\n\n\nRevenue for the Third Quarter 2025\n\n\n\n\n\n \n\n\n\n \n\n\n\nThree Months Ended September 30,\n\n\n\n\n\n(Dollars in 000’s)\n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\nYear-over-Year % Change\n\n\n\n\n\nNucleic Acid Production\n\n\n\n$\n\n\n\n25,353\n\n\n\n \n\n\n\n$\n\n\n\n53,844\n\n\n\n \n\n\n\n(52.9\n\n\n\n)%\n\n\n\n\n\nBiologics Safety Testing\n\n\n\n \n\n\n\n16,277\n\n\n\n \n\n\n\n \n\n\n\n15,181\n\n\n\n \n\n\n\n7.2\n\n\n\n%\n\n\n\n\n\nTotal Revenue\n\n\n\n$\n\n\n\n41,630\n\n\n\n \n\n\n\n$\n\n\n\n69,025\n\n\n\n \n\n\n\n(39.7\n\n\n\n)%\n\n\n\n\n\n\nRevenue for the Nine Months Ended September 30, 2025\n\n\n\n\n\n \n\n\n\n \n\n\n\nNine Months Ended September 30,\n\n\n\n...